Tag: Drugs and Pharmaceuticals

CEDAR PARK, Texas /Florida Newswire - National News/ -- Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled "Cartridge Devices for Administration of a Medicament" (U.S. Patent No. 12329949) and "Hand-Operated Devices for Administration of a Medicament" (EU Patent No. 3946526), further strengthen Zeteo's ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.

SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, "The Market for Implanted Pain Neuromodulation Systems: 2025-2030," the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate.

PHOENIX, Ariz., Aug. 2, 2024 (SEND2PRESS NEWSWIRE) -- SET Enterprises, a leading independent management consulting firm serving the government pricing compliance needs of life sciences manufacturers, today announced the launch of SPI340B℠. This new service offering identifies specific 340B covered entities that exhibit suspicious purchasing patterns that suggest the entire volume of products purchased from pharmaceutical and biotechnology manufacturers may not be dispensed solely to eligible patients of the covered entity.

ATLANTA, Ga., Feb. 1, 2024 (SEND2PRESS NEWSWIRE) -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

DALLAS, Texas, June 13, 2023 (SEND2PRESS NEWSWIRE) -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug benefit and the cost challenges faced by consumers and plan sponsors alike.

DALLAS, Texas, May 1, 2023 (SEND2PRESS NEWSWIRE) -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual 'Trends in Specialty Drug Benefits report.' Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research. PSG has been researching and reporting on drug benefit design for over 10 years.

DALLAS, Texas, Jan. 23, 2023 (SEND2PRESS NEWSWIRE) -- Artemetrx®, the industry's most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.

PFLUGERVILLE, Texas, May 4, 2022 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

REDWOOD CITY, Calif., Dec. 9, 2021 (SEND2PRESS NEWSWIRE) -- Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.

STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

TAMPA, Fla. /Florida Newswire/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021 from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.

AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

AUSTIN, Texas and BIRMINGHAM, Ala., March 11, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

AUSTIN, Texas, March 10, 2021 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

CARY, N.C., Feb. 12, 2021 (SEND2PRESS NEWSWIRE) -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

CHRISTIANSBURG, Va., Oct. 28, 2020 (SEND2PRESS NEWSWIRE) -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.